The purpose of this
study is to explore the anti-inflammatory activity
of
Pterocarpus dalbergioides
fruit
extract (PFE) and the underlying mechanism. Chemical profiling using
ultraperformance liquid chromatography/mass spectrometry identified
28 compounds in PFE (12 flavonoids, 5 fatty acids, 4 phenolic compounds,
3 alkaloids, 2 sesquiterpenes, and 2 xanthophylls). PFE (2 g/kg) significantly
inhibited carrageenan-induced rat paw edema after 4 h of administration
(42% inhibition). A network-based strategy and molecular docking studies
were utilized to uncover the anti-inflammatory mechanism. Out of the
identified compounds, 16 compounds with DL ≥ 0.18 and
F
≥ 30% were selected using bioavailability (
F
) and drug-likeness (DL) metrics. The network analysis
revealed that 90 genes are considered key targets for the selected
compounds and linked to the anti-inflammatory effect. Among all compounds,
linoleic acid was found to be the top-most active constituent as it
targets maximum genes. Four targets (TNF, IL6, AKT1, and CCL2) among
the top 10 genes were found to be the main target genes that may contribute
to the anti-inflammatory potential of PFE. Furthermore, KEGG (Kyoto
encyclopedia of genes and genomes) pathway analysis revealed that
PFE might regulate inflammation through five pathways: neuroactive
ligand–receptor interaction, lipid and atherosclerosis, fluid
shear stress and atherosclerosis, TNF signaling pathway, and rheumatoid
arthritis. The docking study predicted the significant binding affinity
between the top four active constituents (linoleic acid, 9-octadecenoic
acid, 11,12,13-trihydroxy-9-octadecenoic acid, and rhamnetin-3-
O
-rhamnoside) and the selected target proteins (TNF and
AKT1). The findings highlight PFE as a promising drug lead for controlling
inflammation.